What we do Infinium Pharmachem Ltd manufactures iodine-based pharmaceutical intermediates serving pharma, biotech, chemicals, agro, healthcare, and cosmetics industries with over 200 intermediates and 7 APIs. |
Founded in 2,003 |
Market share Leading scale in iodine derivatives with enhanced capacity of 1800 MT p.a., boosting domestic and export market presence. |
Problem solved Provides critical iodine-based intermediates enabling pharma and related sectors to innovate and produce key drugs and chemicals efficiently. |
Top clients or who we serve Pharmaceutical, biotech, specialty chemicals, agrochemical, human and animal health sectors; B2B focus with strategic global clients. |
Key management - |
Our journey and innovations Founded in 2003, converted public in 2022; expanded production capacity and launched IOHEXOL API product; strategic JV in China; new bio-coal subsidiary. |
Where we operate Primarily India with export markets; Joint Venture operations in China; subsidiary in USA and renewable energy initiatives. |
Top products or what we offer Pharmaceutical intermediates, iodine derivatives, new IOHEXOL API, and bio-coal under subsidiaries. |
Top brands Not specified distinct brands; portfolio includes 200+ iodine intermediates and 7+ API products reinforcing market leadership. |
Raw materials needed Iodine and chemical raw materials required for intermediate and API manufacturing. |
Raw materials supplier Not specified in reports. |
Recurring vs cyclical contribution Revenue largely recurring from continuous supply of pharmaceutical intermediates. |
Our industry position Strong position in iodine derivatives manufacturing with capacity expansion and strategic partnerships enhancing competitive edge. |
Financial highlights FY 2025 standalone revenue Rs. 136.9 crore; net profit Rs. 8.47 crore; consolidated revenue Rs. 155.7 crore; profit Rs. 7.84 crore. |
Geographical revenue split Domestic sales Rs. 136.05 crore; exports Rs. 17.13 crore. |
Order book - |
Whats driving growth Capacity expansion, new API launch, strategic JV, and exclusive distribution agreement driving growth. |
Our future plans New contrast media raw materials plant under construction; bio-coal production to double; continued capacity and portfolio expansion. |
Our green promise Operational energy conservation; subsidiary producing bio-coal from agro waste reducing fuel consumption and costs. |
Our people and values Focus on high-performance culture, statutory compliance, and employee safety under POSH and CSR initiatives. |
Key challenges ahead Global economic uncertainties, raw material price risks, compliance, competitive pressures, and operational efficiencies. |
Interesting facts Formed JV in China; launched India’s iodine derivative IOHEXOL API; diversified into green energy through bio-coal production. |
Risks and strategy Mitigates price, economic, and compliance risks via best practices and strategic partnerships with global distributors. |
